Evidence map›Paper›PMID 41950049›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies.

W Hudson Robb, Gurkiran Kaur, Steven Huang, Felipe Martinez, Ba Nguyen, Clifford H Shin, Ming Yang, Christopher T Conyers, Christopher B Grilli, David P Upjohn and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

W Hudson RobbDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.ORCID 0000-0002-8952-7719
Gurkiran KaurDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Steven HuangDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Felipe MartinezDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Ba NguyenDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Clifford H ShinDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Ming YangDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Christopher T ConyersCenter for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Christopher B GrilliCenter for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
David P UpjohnCenter for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Victor E OrtegaCenter for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Richard M KeeganLife Molecular Imaging, Boston, Massachusetts, USA.
Ephraim E ParentDepartment of Radiology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA.
Petrice M CogswellDepartment of Radiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Derek R JohnsonDepartment of Radiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Vijay K RamananDepartment of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Mary Ellen KoranDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.ORCID 0000-0002-3322-9114

Funding

Genetic architecture of age of onset of amyloid positivity: Integrating imaging and genetic tools to identify novel drivers of diseaseK76AG088554 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Mary Ellen Irene Koran · 2024 to 2026
$729k
Alzheimer's Association Clinician Scientist Fellowship (MEK)NIA NIH HHS K76AG088554
6 · The paper itself

Abstract

introductionAnti-amyloid-β (Aβ) therapies are reshaping Alzheimer's disease (AD) management. Understanding changes in real-world patterns of diagnostic testing and infusion chair usage is essential for optimizing access to care.

methodsRetrospective analysis of Mayo Clinic enterprise electronic health records (Jan 2019-Mar 2025) assessed trends in AD-relevant brain imaging, fluid biomarkers, apolipoprotein E (APOE) testing, and lecanemab infusions. Rates of amyloid-beta (Aβ) positivity by sex and age, APOE genotype frequencies, and lecanemab treatment initiation and discontinuation were evaluated.

resultsFollowing national insurance coverage changes, lecanemab infusions grew by 110 infusions per quarter to 605 in Q1 2025. Aβ positron emission tomography scans increased (+22/quarter), cerebrospinal fluid biomarker orders declined (-25/quarter), and plasma p-tau DISCUSSION: The adoption of anti-Aβ therapies coincided with a rapid shift in diagnostic workflows.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAgedAged, 80 and overApolipoproteins EBiomarkersBrainElectronic Health RecordsFemaleHumansMalePositron-Emission TomographyRetrospective Studiestau ProteinsAmyloid beta-PeptidesApolipoproteins EBiomarkerstau ProteinsAlzheimer's diseaseamyloid PETanti‐amyloid therapybiomarkerslecanemabplasma p‐tau217sex differences

Identifiers

PMID41950049
PMCPMC13060759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.